Science
Real-World T-DXd Outcomes in HER2-Mutant NSCLC – IASLC
IASLC/iaslc.org

Real-World T-DXd Outcomes in HER2-Mutant NSCLC – IASLC

International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:

“This multinational cohort examined patients with advanced HER2-mutant NSCLC who were treated with trastuzumab deruxtecan (T-DXd) outside of clinical trials. This evaluation of T-DXd in real-world settings provided new data from a larger group of patients, including those with active brain metastases and treatment-naïve disease, while also suggesting intracranial activity in routine clinical practice.”

 

Title: Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort

Authors: Oliver Illini, Anna-Carina Hund, Hans-Georg Kopp, Mor Moskovitz, Giannis Mountzios, Wolfgang M. Brueckl, Martin Früh, Marie-Elisabeth Leßmann, Petros Christopoulos, Albrecht Stenzinger, Michael Thomas, Roni Gillis, Nir Peled, Fabian Acker, Alfredo Addeo, Andriani Charpidou, Christian Grohé, Horst-Dieter Hummel, Laetitia Mauti, Sacha I. Rothschild, Sabine Schmid, Christian Schumann, Damien Urban, Robert Wurm, Simon Ekman, Marcus Skribek, Franziska Glanemann, Marcel Wiesweg, Christoph Jakob Ackermann, Sofia Agelaki, Petra Hoffknecht, Marko Jakopović, Jens Kern, David König, Katharina Kostenzer, Cornelia Kropf-Sanchen, Eckart Laack, David Lang, Laurenz Nagl, Georg Pall, Martin Reck, Waleed Kian, Anna T. Allemann, Jürgen Alt, David Araújo, Hanibal Bohnenberger, Alexandros Bokas, Hannah Fabikan, Krainer-Jacobs Julie, Christoph Weinlinger, Adrianus Johannes de Langen, Evangelos Georgios Fergadis, Rieke Fischer, Elena Fountzilas, Patrizia Froesch, Nikolaj Frost, Frank Griesinger, Franziska Jordan, Charisios Karanikiotis, Barbara Kiesewetter, Ippokratis Korantzis, Andrea Lopes Machado, Panagiota Economopoulou, Arnold Pilz, Patrick Reimann, Achim Rittmeyer, Akram Saad, Konstantinos Samitas, Karsten Schulmann, Riyaz Shah, Jan Alexander Stratmann, Hossein Taghizadeh, Kai Tammoscheit, Amanda Tufman, Jan-Phillip Weber, Ewald Wöll, Arschang Valipour, Tobias R. Overbeck, Maximilian J. Hochmair
Read the full article.

Real-World T-DXd Outcomes in HER2-Mutant NSCLC - IASLC

AdvanTIG-302: Ociperlimab Plus Tislelizumab Does Not Improve Survival in PD-L1–High NSCLC

Real-World T-DXd Outcomes in HER2-Mutant NSCLC - IASLC

Achim Rittmeyer Adrianus Johannes de Langen Akram Saad Albrecht Stenzinger Alexandros Bokas Alfredo Addeo Amanda Tufman Andrea Lopes Machado Andriani Charpidou Anna T. Allemann Anna-Carina Hund Arnold Pilz Arschang Valipour Barbara Kiesewetter Charisios Karanikiotis Christian Grohe Christian Schumann Christoph Jakob Ackermann Christoph Weinlinger Cornelia Kropf-Sanchen Damien Urban David Araújo David König David Lang Eckart Laack Elena Fountzilas Evangelos Georgios Fergadis Ewald Wöll Fabian Acker Frank Griesinger Franziska Glanemann Franziska Jordan Georg Pall Giannis Mountzios Hanibal Bohnenberger Hannah Fabikan Hans-Georg Kopp Horst-Dieter Hummel Hossein Taghizadeh IASLC Ippokratis Korantzis Jan Alexander Stratmann Jan-Phillip Weber Jens Kern Jürgen Alt Kai Tammoscheit Karsten Schulmann Katharina Kostenzer Konstantinos Samitas Krainer-Jacobs Julie Laetitia Mauti Laurenz Nagl Lung cancer Marcel Wiesweg Marcus Skribek Marie-Elisabeth Leßmann Marko Jakopović Martin Früh Martin Reck Maximilian J. Hochmair Michael Thomas Mor Moskovitz Nikolaj Frost Nir Peled NSCLC Oliver Illini Panagiota Economopoulou Patrick Reimann Patrizia Froesch Petra Hoffknecht Petros Christopoulos Rieke Fischer Riyaz Shah Robert Wurm Roni Gillis Sabine Schmid Sacha I. Rothschild Simon Ekman Sofia Agelaki Tobias R. Overbeck Waleed Kian Wolfgang M. Brueckl